Overview

The Role of Dysbiosis of Gut Microbiota in the Pathogenesis of PCOS.

Status:
Unknown status
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
Polycystic ovary syndrome (PCOS) has a significant impact on women's health, but its pathogenesis is not yet clear. Dysbiosis of gut microbiota may play a role in the pathological change of PCOS. Most of the current researches are still limited to the use of amplicon sequencing to compare the basic taxonomic differences of gut microbiota between PCOS patients and normal controls. Overall analysis of microbiome species, genes, function, metabolism, and immunity in PCOS is still lacked. In this research, we would perform metagenomic sequencing to find the characteristics of gut microbiota of PCOS and to explore their correlations with metabolic, immune, and clinical symptoms. Finally, different interventions (lifestyle interventions, lifestyle interventions + oral probiotic, lifestyle interventions+ compound oral contraceptives) would be used to explore the change of gut microbiome in PCOS patients. This research will not only help the understanding of the pathophysiology of PCOS, but also provide a reference for the selection of clinical treatment options.
Phase:
Phase 3
Details
Lead Sponsor:
Peking Union Medical College Hospital
Collaborator:
Peking Union Medical College
Treatments:
Contraceptive Agents
Contraceptives, Oral
Drospirenone
Drospirenone and ethinyl estradiol combination
Ethinyl Estradiol